Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSabre Insurance Group Regulatory News (SBRE)

Share Price Information for Sabre Insurance Group (SBRE)

Share Price is delayed by 15 minutes
Get Live Data
159.20    1.60 (1.02%)
Bid:
159.20
Ask:
159.80
Spread: 0.60 (0.377%)
Market Cap: £388.94m
SBRE Live PriceLast checked at - London Stock Exchange

Intraday Sabre Insurance Group Share Chart

Pre-Stabilisation Period Announcement

6 Dec 2017 07:15

RNS Number : 4899Y
Barclays Capital Securities Limited
06 December 2017
 

06 December 2017

Not for release, publication or distribution, in whole or in part, directly or indirectly, in or into the United States of America, Australia, Canada, Japan or South Africa or any jurisdiction in which such distribution would be unlawful.

Sabre Insurance Group plc

Pre-Stabilisation Period Announcement

Barclays Bank PLC ('Barclays') (Ben West; telephone: +44 20 7773 9531) hereby gives notice that as Stabilising Coordinator, the Stabilisation Manager named below may stabilise the offer of the following securities in accordance with the Market Abuse Regulation (Regulation (EU) No 596/2014) and the Commission Delegated Regulation (EU) 2016/1052, with the aim of supporting the market price of such securities during the stabilisation period.

 

The securities:

Issuer:

Sabre Insurance Group plc

Aggregate nominal amount/Offering size:

125,000,000 Ordinary Shares (excluding the over-allotment option)

Description:

Ordinary Shares in Sabre Insurance Group plc with a nominal value of £0.001. ISIN: GB00BYWVDP49

Offer price;

 230p

Stabilisation:

Stabilisation Manager:

Barclays Capital Securities Limited, 5 The North Colonnade, Canary Wharf, London, E14 4BB, United Kingdom

Stabilisation period expected to start on:

 6th December 2017 (approximately 08.00 a.m.)

Stabilisation period expected to end no later than:

 5th January 2018 (close of business)

Existence, maximum size and conditions of use of over-allotment facility:

The Stabilisation Manager(s) may over-allot the securities to the extent permitted in accordance with applicable law up to a maximum size of 12,500,000 Ordinary Shares

Existence, maximum size, exercise period and conditions of use of Over-allotment Option:

In connection with the IPO, the Stabilising Manager may, for stabilisation purposes, over-allot Shares up to a maximum of 12,500,000 Ordinary Shares

Stabilisation Trading Venue:

London Stock Exchange

 

In connection with the offer of the above securities, the Stabilisation Manager may over-allot the securities or effect transactions with a view to supporting the market price of the securities at a level higher than that which might otherwise prevail. However, stabilisation may not necessarily occur and any stabilisation action, if begun, may cease at any time. Any stabilisation action or overallotment shall be conducted in accordance with all applicable laws and rules.

This announcement is for information purposes only and does not constitute an invitation or offer to underwrite, subscribe for or otherwise acquire or dispose of any securities of the Issuer in any jurisdiction.

This announcement is only addressed to and directed at persons outside the United Kingdom and persons in the United Kingdom who have professional experience in matters related to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the Order) or who are high net worth persons falling within Article 49 of the Order and must not be acted on or relied on by other persons in the United Kingdom.

In addition, if and to the extent that this announcement is communicated in any EEA Member State that has implemented Directive 2003/71/EC (together with any applicable implementing measures in any Member State, the "Prospectus Directive") before the publication of a prospectus in relation to the securities to which this announcement relates which has been approved by the competent authority in that Member State in accordance with the Prospectus Directive (or which has been approved by a competent authority in another Member State and notified to the competent authority in that Member State in accordance with the Prospectus Directive), this announcement is only addressed to and directed at persons in that Member State who are qualified investors within the meaning of the Prospectus Directive (or who are other persons to whom the offer may lawfully be addressed) and must not be acted on or relied on by other persons in that Member State.

This announcement does not constitute, or form part of, an offer to sell, or a solicitation of an offer to purchase any securities in the United States or any other jurisdiction. The securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States except to "qualified institutional buyers" as defined in, and in reliance on, Rule 144A under the Securities Act or another exemption from, or transaction not subject to, the registration requirements of the Securities Act. All offers and sales of securities outside of the United States will be made in reliance on, and in compliance with, Regulation S under the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offering of the securities in the United States.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
STAMMMGZMKRGNZZ
Date   Source Headline
2nd Jun 20267:00 amRNSOn-market Share Buyback Programme of £5m
27th May 20269:36 amRNSDirector Declaration
21st May 202611:20 amRNSResult of AGM
21st May 20267:00 amRNSTrading Update
12th May 20261:22 pmRNSDirector/PDMR Shareholding
22nd Apr 20261:18 pmRNSDirector/PDMR Shareholding
14th Apr 20263:48 pmRNSDirector/PDMR Shareholding
13th Apr 20263:18 pmRNSDirector/PDMR Shareholding
8th Apr 20262:56 pmRNSDirector/PDMR Shareholding
8th Apr 202610:41 amRNSDirector/PDMR Shareholding
8th Apr 202610:39 amRNSDirector/PDMR Shareholding
30th Mar 202611:01 amRNSNotice of AGM
11th Mar 20261:49 pmRNSDirector/PDMR Shareholding
10th Mar 20267:00 amRNSFull-year results 2025
11th Feb 20261:27 pmRNSDirector/PDMR Shareholding
13th Jan 20263:43 pmRNSDirector/PDMR Shareholding
11th Dec 20251:29 pmRNSDirector/PDMR Shareholding
11th Nov 20251:40 pmRNSDirector/PDMR Shareholding
31st Oct 20258:00 amRNSTotal Voting Rights
23rd Oct 20259:58 amRNSDirector/PDMR Shareholding
16th Oct 20257:00 amRNSTrading Update
14th Oct 20257:49 amRNSHolding(s) in Company
13th Oct 20253:56 pmRNSDirector/PDMR Shareholding
3rd Oct 20257:00 amRNSCompletion of Buyback Programme
3rd Oct 20257:00 amRNSTransaction in Own Shares
2nd Oct 20257:00 amRNSTransaction in Own Shares
1st Oct 20257:00 amRNSTransaction in Own Shares
30th Sep 202510:21 amRNSTotal Voting Rights
30th Sep 20257:00 amRNSTransaction in Own Shares
29th Sep 20257:00 amRNSTransaction in Own Shares
26th Sep 20257:00 amRNSTransaction in Own Shares
25th Sep 20251:01 pmRNSDirector/PDMR Shareholding
25th Sep 20257:00 amRNSTransaction in Own Shares
24th Sep 20257:00 amRNSTransaction in Own Shares
23rd Sep 20257:00 amRNSTransaction in Own Shares
22nd Sep 20257:00 amRNSTransaction in Own Shares
19th Sep 20257:00 amRNSTransaction in Own Shares
18th Sep 20254:52 pmRNSHolding(s) in Company
18th Sep 20257:00 amRNSTransaction in Own Shares
17th Sep 20257:00 amRNSTransaction in Own Shares
16th Sep 20257:00 amRNSTransaction in Own Shares
15th Sep 20257:00 amRNSTransaction in Own Shares
12th Sep 20257:00 amRNSTransaction in Own Shares
11th Sep 202512:24 pmRNSDirector/PDMR Shareholding
11th Sep 20257:00 amRNSTransaction in Own Shares
10th Sep 20257:00 amRNSTransaction in Own Shares
9th Sep 20257:00 amRNSTransaction in Own Shares
8th Sep 20257:00 amRNSTransaction in Own Shares
5th Sep 20257:00 amRNSTransaction in Own Shares
4th Sep 20257:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.